Arovella R&D tax rebate of $4.03 million
Arovella Therapeutics Ltd (ASX: ALA) ACN 090 987 250 (Arovella or the Company) is pleased to announce that it has received an FY2026 R&D Tax Incentive refund of $4.03 million. These funds further strengthen Arovella’s cash position as it progresses development of its lead asset and the dosing of its first patient.
Acting CEO, Dr Nicole van der Weerden, noted, “The $4.03 million R&D tax refund further strengthens execution of our clinical and development programs. Arovella is well placed to advance the Phase 1 trial through safety and efficacy, while progressing ALA-105 towards the clinic.”
The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development.